Protocol Ledger

NCT05512364 · Phase III · RECRUITING

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Interventional Phase III clinical trial protocol NCT05512364 sponsored by European Organisation for Research and Treatment of Cancer - EORTC in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-15 Enrollment: 220 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05512364
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)220 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05512364
Protocol FieldVerified Registry Value
NCT IdentifierNCT05512364
Consolidated Lead SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment220 participants (ESTIMATED)
Registered Start Date2023-12-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05512364
Hospital Research SiteLocationSite Profile
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI